Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX (daratumumab) – making it the first authorised treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results